PEE4: THE FRENCH VERSION OF THE PSORIASIS DISABILITY INDEX  by Finlay, A et al.
Abstracts 119
the genetic test resulted in an incremental cost-effective-
ness ratio was $32,633 per QALY gained. Sensitivity
analysis produced results ranging from increased costs of
$300,430 and 3.6 additional cases of severe periodontitis
(per one thousand patients) to cost savings of $830,140
and 52.8 fewer cases of severe periodontitis. Sources of
uncertainty were 1) patient compliance based on test re-
sult, 2) effectiveness of non-surgical therapy, and 3) the
relative risk for progression based on genotype. CON-
CLUSION: The use of genetic testing to guide treatment
for periodontitis may result in a wide range of outcomes
under different modeling scenarios. These results range
from improved patient health and cost-savings to addi-
tional costs and poorer health. Economic modeling has
identified the additional data required to determine if IL-1
testing can be implemented in a primary care setting in a
cost-effective manner. These methods may be used by the
health insurance industry to assess the cost-effectiveness
of genetic testing for predisposition towards other dis-
eases.
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OBJECTIVE: This study investigates the incremental cost
of dry eye disease (keratitis sicca) in a managed care pop-
ulation. METHODS: Patients with dry eye diagnoses
(ICD-9-CM  370.33, 375.15, 710.2) or punctal occlu-
sion procedures (CPT-4  68760, 68761) during 1997–
1998 were identified from PharMetrics’ Integrated Out-
comes database of 7 million patients. Controls were ran-
domly selected and matched 1:1 to dry eye cases on age
category, gender and managed care plan. Costs were cal-
culated for 6 months before and after the first dry eye-
related claim for cases, or the midpoint of claims history
for controls. RESULTS: The prevalence of dry eye dis-
ease was 0.48% in 1997 and 0.39% in 1998. Dry eye pa-
tients (n  31,683) were more likely than controls to use
ophthalmic medications, many of which are not indicated
for dry eye (P  .001). Use of non-ophthalmic medications
was similar between cohorts. Total charges rose $454.79
(22.2%) for dry eye patients, significantly more than for
controls ($289.48 [15.9%]) (P  .001). This was mostly
due to a rise in outpatient charges ($257.40 [28.7%] for
cases versus $76.14 [11.2%] for controls). Dry eye diag-
noses/procedures were associated with greater increases
in outpatient charges, pharmacy charges, and total medi-
cal charges (P  .0001). Dry eye patients experienced a
greater average increase in total medical costs than did con-
trols, mostly arising from outpatient charges. CONCLU-
SION: We conclude that a major factor in dry eye-related
cost increases is additional physician visits, which may be
a consequence of the ineffectiveness of available therapies.
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OBJECTIVE: The objective of our work was to translate
the PDI into French, with careful attention to the linguis-
tic aspects and the cultural context of the French patients.
CONTEXT: The PDI is a scale devised by Prof. A. Finlay
of Cardiff to evaluate the impact of psoriasis on the life
of the patient. This questionnaire has been used in nu-
merous studies to evaluate the consequences of the dis-
ease in daily life or the effects of different treatments. RE-
SULTS: With the author’s approval, the questionnaire
was translated from English to French by two indepen-
dent translators. The two versions were compared and a
few non significant differences were noted. A third trans-
lation from English to French was realized with the assis-
tance of the APLCP, psoriasis patient support group.
When compared to the first two, this third translation
brought out the specificity of the French cultural context
and the reality of the disease. To make sure that the
translation was consistent with our objective, the ques-
tionnaire was sent to five patients and translated from
French to English by two independent translators. For a
large-scale validation, this questionnaire was sent by post
to 5000 psoriasis patients belonging to the APLCP. With
the addition of a questionnaire on the patient’s behavior
in respect to the treatment, “Living With Psoriasis” will
make it possible to evaluate every two years the impact
and the daily consequences of psoriasis on French pa-
tients and thus become a decision support tool. CON-
CLUSION: The novelty of this initiative resides in the in-
volvement of a patient support group at every step on a
level rarely attained, not only in the translation but also
in the validation of the questionnaire. This close involve-
ment reflects the key role of a patient support group in
the management of the disease.
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OBJECTIVES: To examine physician prescribing pattern
of antibiotics for otitis media in children and compare
them with therapeutic guidelines issued by the American
Academy of Pediatrics, Family Physicians, and Otolaryn-
gology, for appropriateness. Also, to calculate the cost
savings that could be achieved by adhering to the guide-
